All News
Intravenous Immune Globulin in Dermatomyositis
Few drugs have been studied well in the treatment of dermatomyositis (DM) and only recently has intravenous immune globulin (IVIG) been granted FDA approval for the treatment of DM, based on this pivotal trial.
Read ArticleTofacitinib shows promise in scleroderma
Systemic sclerosis is one of the rarest autoimmune diseases, affecting roughly 100,000 people (primarily women) in the U.S. With no licensed treatments available for this subset of scleroderma patients, rheumatology researchers are searching for opportunities to use resources and technology that have proven beneficial in treating other autoimmune and rheumatic diseases.
Read ArticleOrthopedic surgery patients do fine without opioid painkillers
Hamilton, ON (Oct. 4, 2022) – Patients can recover from orthopedic surgery just as well without using opioid-based painkillers, says a McMaster University and Hamilton Health Sciences (HHS) study published by the Journal of the American Medical Association (JAMA).
Read ArticleTransitioning JIA to Adult Care is Problematic
Juvenile idiopathic arthritis (JIA) may start in adolescence and extend into adulthood.
Read ArticleIL-17 Switching Works in Psoriatic Disease
Analysis of data from a Czech nationwide registry of psoriatic patients receiving biologic or targeted therapies (BIOREP) has shown a high success rate when switching between specific IL-17 inhibitors.
Read ArticleGreat and Not So Great (9.30.2022)
This week it's the great and not-so-great on gout, chondrocalcinosis, osteoporosis and misdiagnosis. We are good at many of those things - what's not so great? Let's review the news and journal reports from the past week on RheumNow.
Read ArticleEfficacy and Safety of JAK Inhibitors in Psoriatic Disease
There is a growing body of evidence demonstrating efficacy and safety of JAK inhibitors in patients with moderate-to-severe psoriasis and psoriatic arthritis, according to a systematic review in BMC Rheumatology.
NSAIDs Linked to Heart Failure in Diabetes Patients
Short-term use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a first-time hospitalisation for heart failure in patients with type 2 diabetes, according to research presented at ESC Congress 2022.
Read ArticleAre We Overcautious With TNF Inhibitors in Pregnancy?
What may seem like a prudent approach to treatment of inflammatory bowel disease (IBD) in pregnant women actually represents an overabundance of caution, suggested researchers who found no increased risk from tumor necrosis factor (TNF) inhibitors.
Read Article
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)


